Publication of change in the total number of shares and votes in Diamyd
As of September 30, 2010, the share capital in Diamyd Medical AB (publ.)
is 14,583,905 SEK. The total number of votes is 4,210,869 and the total
number of shares is 29,167,810, divided among 1,437,876 shares of series
A (1 vote) and 27,729,934 shares of series B (1/10 vote).
This change is due to the exercise of granted employee stock options in
the stock option plan of 2007/2010, approved by the Annual Meeting of
Shareholders 2007.
For more information, please contact:
Elisabeth Lindner, President and CEO Diamyd Medical AB (publ.)
Phone: +46 8 661 0026
For pictures and press material, please contact:
Andreas Ericsson, Diamyd Medical AB (publ.)
andreas.ericsson@diamyd.com
Phone: +46 8 661 0026
About Diamyd Medical
Diamyd Medical is a Swedish diabetes company focusing on the development
of pharmaceuticals for the treatment of autoimmune diabetes and its
complications. The company's most advanced project is the GAD-based drug
Diamyd® for type 1 diabetes. Phase III trials for this drug are in
progress in both Europe and the US. In 2010 the company signed an
agreement with Ortho-McNeil-Janssen Pharmaceuticals, Inc., a Johnson &
Johnson company, to develop and commercialize the Diamyd® diabetes
therapy. In addition, the company has initiated clinical studies in the
US in the area of chronic pain, using its Nerve Targeting Drug Delivery
System (NTDDS). The company has also out-licensed the use of GAD for the
treatment of Parkinson's disease.
Diamyd Medical has offices in Sweden and in the US. Shares are listed on
Nasdaq OMX in Stockholm (ticker: DIAM B) and on OTCQX in the US (ticker:
DMYDY) administered by the Pink OTC Markets and the Bank of New York
Mellon (PAL). Further information is available on the company's website:
www.diamyd.com.
This information is disclosed in accordance with the Swedish Securities
Markets Act, the Swedish Financial Instruments Trading Act, or the
requirements stated in the listing agreements.
Diamyd Medical AB (publ.)
Karlavägen 108, SE-115 26 Stockholm, Sweden. Tel: +46 (0)8 6610026, Fax:
+46 (0)8 661 63 68
E-mail: info@diamyd.com. VAT no: SE556530-142001.
